This development marks a crucial step forward in SMSbiotech's efforts to address this debilitating respiratory condition. The Phase I trial, conducted in Australia, will be the first human trial of ...

Cardiovascular diseases and diabetes are some of the most common coexisting conditions in COPD. Shared risk factors and overlapping physiological processes likely contribute to the high rate of ...

SMSbiotech has announced a significant milestone in its pursuit of its regenerative medicine technology, securing approval to commence a Phase I clinical trial in Australia (registration number: ...